RET and non-small cell lung carcinoma: Multiple trials have demonstrated that MKIs, such as vandetanib and cabozantinib, have favorable efficacy in patients with RET-altered NSCLC, and these two agents have been approved by the FDA to treat RET-altered NSCLC96,97.